(Q34636653)

3 August 2017

1 reference

title

Ziprasidone: a review of its use in schizophrenia and schizoaffective disorder. (English)

1 reference

3 August 2017

0 references

3

Gillian M Keating

1 reference

3 August 2017

Nishan S Gunasekara

1

1 reference

3 August 2017

Caroline M Spencer

series ordinal

2

1 reference

3 August 2017

publication date

1 January 2002

1 reference

3 August 2017

1 reference

3 August 2017

volume

62

1 reference

3 August 2017

issue

8

1 reference

3 August 2017

page(s)

1217-1251

1 reference

The Mechanism of Action of Novel Antipsychotic Drugs

3 August 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00003495-200262080-00015

Identification of the major human liver cytochrome P450 isoform(s) responsible for the formation of the primary metabolites of ziprasidone and prediction of possible drug interactions

21 January 2018

1 reference

12 December 2020

Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death

1 reference

12 December 2020

The ratios of serotonin2 and dopamine2 affinities differentiate atypical and typical antipsychotic drugs

1 reference

12 December 2020

Suicide among schizophrenics: a comparison of attempters and completed suicides

1 reference

12 December 2020

Metabolism and excretion of a new antipsychotic drug, ziprasidone, in humans

1 reference

12 December 2020

The nature and prevalence of depression in chronic schizophrenic in-patients

1 reference

12 December 2020

The time course of binding to striatal dopamine D2 receptors by the neuroleptic ziprasidone (CP-88,059-01) determined by positron emission tomography.

1 reference

12 December 2020

An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder

1 reference

12 December 2020

Depression, attempted suicide, and suicide in patients with chronic schizophrenia

1 reference

12 December 2020

Depression in chronic schizophrenia

1 reference

12 December 2020

Ziprasidone and the pharmacokinetics of a combined oral contraceptive

1 reference

12 December 2020

Typical and atypical antipsychotic occupancy of D2 and S2 receptors: an autoradiographic analysis in rat brain

1 reference

12 December 2020

Measuring the costs of schizophrenia. Implications for the post-institutional era in the US.

1 reference

12 December 2020

The pharmacokinetics of ziprasidone in healthy volunteers treated with cimetidine or antacid

1 reference

12 December 2020

5-HT(1A) receptor activation contributes to ziprasidone-induced dopamine release in the rat prefrontal cortex

1 reference

12 December 2020

Intramuscular ziprasidone, 2 mg versus 10 mg, in the short-term management of agitated psychotic patients

1 reference

12 December 2020

Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group

1 reference

12 December 2020

The current unsatisfactory state of relapse prevention in schizophrenic psychoses--suggestions for improvement

1 reference

12 December 2020

The effects of ziprasidone on steady-state lithium levels and renal clearance of lithium

1 reference

12 December 2020

Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: a double-blind, randomized trial

1 reference

12 December 2020

Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity

1 reference

12 December 2020

The effect of carbamazepine on the steady-state pharmacokinetics of ziprasidone in healthy volunteers

1 reference

12 December 2020

Interaction of antipsychotic drugs with neurotransmitter receptor sites in vitro and in vivo in relation to pharmacological and clinical effects: role of 5HT2 receptors

1 reference

12 December 2020

Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia

1 reference

12 December 2020

Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence

1 reference

12 December 2020

Depression and Social Adjustment Among Chronic Schizophrenic Outpatients

1 reference

12 December 2020

Ziprasidone: pharmacology, clinical progress and therapeutic promise

1 reference

12 December 2020

Dose dependent occupancy of central dopamine D2 receptors by the novel neuroleptic CP-88,059-01: a study using positron emission tomography and 11C-raclopride

1 reference

12 December 2020

Ziprasidone and the activity of cytochrome P450 2D6 in healthy extensive metabolizers

1 reference

12 December 2020

The effect of timing of a standard meal on the pharmacokinetics and pharmacodynamics of the novel atypical antipsychotic agent ziprasidone.

1 reference

12 December 2020

Drug treatment of the negative symptoms of schizophrenia

1 reference

12 December 2020

Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial

1 reference

12 December 2020

Single- and multiple-dose pharmacokinetics of ziprasidone under non-fasting conditions in healthy male volunteers

1 reference

12 December 2020

Single- and multiple-dose pharmacokinetics of ziprasidone in healthy young and elderly volunteers

1 reference

12 December 2020

Antipsychotic-induced weight gain: a comprehensive research synthesis

1 reference

12 December 2020

Antipsychotic-associated weight gain and clinical outcome parameters

1 reference

12 December 2020

New drugs for the treatment of schizophrenic patients

1 reference

12 December 2020

The pharmacology of weight gain with antipsychotics.

1 reference

12 December 2020

Relapse in schizophrenia

1 reference

12 December 2020

Positron emission tomographic analysis of central 5-hydroxytryptamine2 receptor occupancy in healthy volunteers treated with the novel antipsychotic agent, ziprasidone.

1 reference

12 December 2020

Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values

1 reference

12 December 2020

1 reference

12 December 2020

The pharmacokinetics of ziprasidone in subjects with normal and impaired hepatic function

1 reference

12 December 2020

The effects of ketoconazole on ziprasidone pharmacokinetics--a placebo-controlled crossover study in healthy volunteers

1 reference

12 December 2020

Atypical antipsychotic drugs as a first-line treatment of schizophrenia: a rationale and hypothesis.

1 reference

12 December 2020

The pharmacokinetics of ziprasidone in subjects with normal and impaired renal function

1 reference

12 December 2020

Ziprasidone treatment of children and adolescents with Tourette's syndrome: a pilot study

1 reference

12 December 2020

Intramuscular ziprasidone compared with intramuscular haloperidol in the treatment of acute psychosis. Ziprasidone I.M. Study Group.

1 reference

12 December 2020

10.2165/00003495-200262080-00015

Identifiers

DOI

1 reference

Dimensions Publication ID

3 August 2017

1016671686

0 references

1 reference